Schafer Cullen Capital Management Inc. Boosts Holdings in Sanofi (SNY)
Schafer Cullen Capital Management Inc. raised its position in shares of Sanofi (NYSE:SNY) by 9.6% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,017,072 shares of the company’s stock after acquiring an additional 88,785 shares during the quarter. Schafer Cullen Capital Management Inc.’s holdings in Sanofi were worth $48,728,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of the business. BB&T Investment Services Inc. bought a new stake in Sanofi during the 2nd quarter valued at approximately $746,000. Wilbanks Smith & Thomas Asset Management LLC boosted its position in Sanofi by 0.9% during the 2nd quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 71,517 shares of the company’s stock valued at $3,426,000 after acquiring an additional 651 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in Sanofi by 15.3% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 71,843 shares of the company’s stock valued at $3,442,000 after acquiring an additional 9,513 shares in the last quarter. Quadrant Capital Group LLC boosted its position in Sanofi by 7.0% during the 2nd quarter. Quadrant Capital Group LLC now owns 5,909 shares of the company’s stock valued at $264,000 after acquiring an additional 384 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in Sanofi during the 2nd quarter valued at approximately $2,702,000. 9.33% of the stock is currently owned by institutional investors and hedge funds.
Several analysts have weighed in on SNY shares. BidaskClub raised Sanofi from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Cowen and Company reaffirmed a “market perform” rating and set a $52.00 price objective (up from $46.00) on shares of Sanofi in a research report on Tuesday, August 1st. HSBC Holdings plc raised Sanofi from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 30th. Argus reaffirmed a “buy” rating and set a $55.00 price objective on shares of Sanofi in a research report on Friday, September 1st. Finally, J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $53.50.
Sanofi (NYSE:SNY) last posted its earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.74. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The company had revenue of $8.66 billion during the quarter, compared to analysts’ expectations of $8.71 billion. The business’s revenue was down 2.3% compared to the same quarter last year.
In other news, major shareholder Sanofi bought 105,820 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The stock was bought at an average price of $482.04 per share, with a total value of $51,009,472.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.00% of the company’s stock.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.